Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neha Korde

Showing results (31-40 of 125) with videos related to

Pageof 13
Sort By:
Leukemia & Lymphoma|November 23, 2013
The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myelomaElisabet E Manasanch, Neha Korde, Adriana Zingone, et al.
JAMA Oncology|July 17, 2015
The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple MyelomaElin Edda Sigurdardottir, Ingemar Turesson, Sigrun Helga Lund, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 24, 2014
Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic reviewCharlene M McShane, Liam J Murray, Ola Landgren, et al.
Obesity (Silver Spring, Md.)|June 12, 2017
Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor DiseaseJonathan N Hofmann, Sham Mailankody, Neha Korde, et al.
American Journal of Hematology|November 22, 2012
Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced ageBenjamin M Cherry, Rene Costello, Adriana Zingone, et al.
Scientific Reports|October 18, 2019
Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomidePhoebe A Huang, Shaunna L Beedie, Cindy H Chau, et al.
Blood Cancer Journal|February 6, 2019
Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patientsDickran Kazandjian, Elizabeth Hill, Malin Hultcrantz, et al.
Leukemia & Lymphoma|July 15, 2022
Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot studySham Mailankody, Meghan Salcedo, Elizabet Tavitian, et al.
Bone Marrow Transplantation|May 6, 2018
Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myelomaNishant Tageja, Neha Korde, Dickran Kazandjian, et al.
Leukemia & Lymphoma|August 7, 2013
Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphomaElisabet E Manasanch, Raul Braylan, Maryalice Stetler-Stevenson, et al.
Pageof 13

Showing results (31-40 of 125) with videos related to

Sort By:
Pageof 13
Leukemia & Lymphoma|November 23, 2013
The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myelomaElisabet E Manasanch, Neha Korde, Adriana Zingone, et al.
JAMA Oncology|July 17, 2015
The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple MyelomaElin Edda Sigurdardottir, Ingemar Turesson, Sigrun Helga Lund, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 24, 2014
Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic reviewCharlene M McShane, Liam J Murray, Ola Landgren, et al.
Obesity (Silver Spring, Md.)|June 12, 2017
Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor DiseaseJonathan N Hofmann, Sham Mailankody, Neha Korde, et al.
American Journal of Hematology|November 22, 2012
Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced ageBenjamin M Cherry, Rene Costello, Adriana Zingone, et al.
Scientific Reports|October 18, 2019
Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomidePhoebe A Huang, Shaunna L Beedie, Cindy H Chau, et al.
Blood Cancer Journal|February 6, 2019
Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patientsDickran Kazandjian, Elizabeth Hill, Malin Hultcrantz, et al.
Leukemia & Lymphoma|July 15, 2022
Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot studySham Mailankody, Meghan Salcedo, Elizabet Tavitian, et al.
Bone Marrow Transplantation|May 6, 2018
Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myelomaNishant Tageja, Neha Korde, Dickran Kazandjian, et al.
Leukemia & Lymphoma|August 7, 2013
Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphomaElisabet E Manasanch, Raul Braylan, Maryalice Stetler-Stevenson, et al.
Pageof 13